COMPUGEN LTD (CGEN)
Data as of , from SEC Form 4 filings.
See up to 3 months of CGEN. The 7-day demo opens the 1M and 3M ranges and puts CGEN on your watchlist.
Start 7-day demoLatest CGEN insider trades
About COMPUGEN LTD (CGEN)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
- 75
- 2000
- XNAS
CGEN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 21 | 618,500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CGEN insider transactions (Form 4)
6022 Form 4 filings on record, the earliest from Mar 30, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Zurit Levine - Officer | Grant or award | Ordinary Shares | 18,000 footnote F1 | $0.00 | - | |
| Zurit Levine - Officer | Grant or award | Share Option (right to buy) | 24,000 | $0.00 | - | |
| ||||||
| David Silberman - Officer | Grant or award | Ordinary Shares | 19,500 footnote F1 | $0.00 | - | |
| David Silberman - Officer | Grant or award | Share Option (right to buy) | 26,000 | $0.00 | - | |
| ||||||
 Eran Ophir - Officer | Grant or award | Share Option (right to buy) | 200,000 | $0.00 | - | |
| Anat Cohen-Dayag - Director | Grant or award | Share Option (right to buy) | 100,000 | $0.00 | - | |
| Eran Perry - Director | Grant or award | Ordinary Shares | 7,500 footnote F1 | $0.00 | - | |
| Eran Perry - Director | Grant or award | Share Option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Pierre Ferre - Officer | Grant or award | Share Option (right to buy) | 70,000 | $0.00 | - | |
| Russo Sharon Kredo - Officer | Grant or award | Ordinary Shares | 18,000 footnote F1 | $0.00 | - | |
| Russo Sharon Kredo - Officer | Grant or award | Share Option (right to buy) | 24,000 | $0.00 | - | |
| ||||||
| Savitzky Kinneret Livnat - Director | Grant or award | Ordinary Shares | 7,500 footnote F1 | $0.00 | - | |
| Savitzky Kinneret Livnat - Director | Grant or award | Share Option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Mathias Hukkelhoven - Director | Grant or award | Ordinary Shares | 7,500 footnote F1 | $0.00 | - | |
| Mathias Hukkelhoven - Director | Grant or award | Share Option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Gilead Halevy - Director | Grant or award | Ordinary Shares | 7,500 footnote F1 | $0.00 | - | |
| Gilead Halevy - Director | Grant or award | Share Option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Sanford S. Zweifach - Director | Grant or award | Ordinary Shares | 7,500 footnote F1 | $0.00 | - | |
| Sanford S. Zweifach - Director | Grant or award | Share Option (right to buy) | 10,000 | $0.00 | - | |
| ||||||
| Michelle Mahler - Officer | Grant or award | Ordinary Shares | 13,500 footnote F1 | $0.00 | - | |
| Michelle Mahler - Officer | Grant or award | Share Option (right to buy) | 18,000 | $0.00 | - | |
| ||||||
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 1,875 | $0.83 | $2K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 1,875 | $2.50 | $5K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 1,875 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 2,000 | $1.15 | $2K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 2,000 | $3.20 | $6K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 2,000 | $0.00 | - | |
| Eran Ophir - Officer | Option exercise | Ordinary Shares | 5,000 | $0.83 | $4K | |
| Eran Ophir - Officer | Open-market sale | Ordinary Shares | 5,000 | $3.20 footnote F2 | $16K | |
| Eran Ophir - Officer | Option exercise | Share Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Eran Ophir - Officer | Option exercise | Ordinary Shares | 5,000 | $0.83 | $4K | |
| Eran Ophir - Officer | Open-market sale | Ordinary Shares | 5,000 | $2.90 footnote F2 | $15K | |
| Eran Ophir - Officer | Option exercise | Share Option (right to buy) | 5,000 | $0.00 | - | |
| ||||||
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 2,000 | $1.15 | $2K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 2,000 | $2.80 | $6K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 2,000 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 1,125 | $0.83 | $933 | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 2,000 | $1.15 | $2K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 3,125 | $2.56 footnote F2 | $8K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 1,125 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 2,000 | $0.00 | - | |
| ||||||
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 2,500 | $0.83 | $2K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 2,500 | $2.30 | $6K | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 4,375 | $0.83 | $4K | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 1,000 | $1.15 | $1K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 5,375 | $2.42 | $13K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 2,500 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 4,375 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 1,000 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 2,500 | $0.83 | $2K | |
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 1,000 | $1.15 | $1K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 3,500 | $2.20 | $8K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 2,500 | $0.00 | - | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 1,000 | $0.00 | - | |
| Eran Ophir - Officer | Option exercise | Ordinary Shares | 5,625 | $0.83 | $5K | |
| Eran Ophir - Officer | Open-market sale | Ordinary Shares | 5,625 | $2.21 footnote F2 | $12K | |
| Eran Ophir - Officer | Option exercise | Share Option (right to buy) | 5,625 | $0.00 | - | |
| ||||||
| Zurit Levine - Officer | Option exercise | Ordinary Shares | 11,875 | $0.83 | $10K | |
| Zurit Levine - Officer | Open-market sale | Ordinary Shares | 11,875 | $2.04 footnote F2 | $24K | |
| Zurit Levine - Officer | Option exercise | Share Option (right to buy) | 11,875 | $0.00 | - | |
| ||||||
Recent CGEN Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
CGEN insider trading FAQ
What is the latest insider trade for CGEN?
COMPUGEN LTD (CGEN) had 12 insider filings in the last 90 days, with the most recent on 2026-07-30. The full record for CGEN runs to 22 Form 4 filings, the earliest from 2026-03-30. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CGEN stock?
No insider purchases of CGEN were filed in the last 90 days.
How many insiders are selling CGEN stock?
No insider sales of CGEN were filed in the last 90 days. 11 sales are on record for this company.
Where can I see CGEN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CGEN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Zurit Levine view on EDGAR
- - David Silberman view on EDGAR
- - Eran Ophir view on EDGAR
- - Anat Cohen-Dayag view on EDGAR
- - Eran Perry view on EDGAR
- - Pierre Ferre view on EDGAR
- - Russo Sharon Kredo view on EDGAR
- - Savitzky Kinneret Livnat view on EDGAR
- - Mathias Hukkelhoven view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CGEN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CGEN with a 7-day demo
- CGEN on your watchlist
- Every CGEN Form 4 filing on record
- Up to 3 months of CGEN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
